Biomind Financial Statements From 2010 to 2025
| BMNDF Stock | USD 0.11 0.02 22.77% |
Check Biomind Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomind Labs' main balance sheet or income statement drivers, such as , as well as many indicators such as . Biomind financial statements analysis is a perfect complement when working with Biomind Labs Valuation or Volatility modules.
Biomind |
Biomind Labs Company Shares Outstanding Analysis
Biomind Labs' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biomind Labs Shares Outstanding | 74.76 M |
Most of Biomind Labs' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomind Labs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Biomind Labs has 74.76 M of shares currently outstending. This is 58.59% lower than that of the Healthcare sector and 30.03% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 86.93% higher than that of the company.
Biomind Labs Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biomind Labs's current stock value. Our valuation model uses many indicators to compare Biomind Labs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomind Labs competition to find correlations between indicators driving Biomind Labs's intrinsic value. More Info.Biomind Labs is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomind Labs' earnings, one of the primary drivers of an investment's value.About Biomind Labs Financial Statements
Biomind Labs stakeholders use historical fundamental indicators, such as Biomind Labs' revenue or net income, to determine how well the company is positioned to perform in the future. Although Biomind Labs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biomind Labs' assets and liabilities are reflected in the revenues and expenses on Biomind Labs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biomind Labs. Please read more on our technical analysis and fundamental analysis pages.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. Biomind Labs is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Biomind Pink Sheet
Biomind Labs financial ratios help investors to determine whether Biomind Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomind with respect to the benefits of owning Biomind Labs security.